Pfizer Gets Support For Arthritis Drug Approval

Pfizer Inc. (NYSE:PFE) has moved one step closer to approval of a drug that will improve options in the treatment of Rheumatoid Arthritis. An advisory panel specializing in arthritis medication voted 8-2 in favor of the drug stating that it's benefits outweighed its potential risks. The support of the committee brings the company one step closer to approval of the drug, which could be a boon to the company's future sales.

The medication, known as tofacitinib, is an oral drug in contrast to many of the other rheumatoid arthritis drugs on the market which tend to be injectable. The easier...